Expert Interview
A Third Look: Discussing the standard of care and the potential of Janssen Pharma's TREMFYA along with the VISIBLE Phase 3b Study of TREMFYA® (Guselkumab) in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
Ticker(s): JNJ- Treats Approximately 90 patients per month with plaque psoriasis
- Has read the publicly available information and can discuss Tyk2 clinically and how they will be a part of the treatment modalities.
- Dermatologist and clinical faculty at the University of Pennsylvania
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
